 Adagio Therapeutics Incs NASDAQ: ADGI Phase 23 trials evaluating 300 mg adintrevimab ADG20 as pre-and-post-exposure prophylaxis EVADE and treatment STAMP for COVID-19 have met its primary endpoints. Following the emergence of the omicron variant, a pre-specified exploratory. 